These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8666917)

  • 1. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.
    Junghans RP; Waldmann TA
    J Exp Med; 1996 Apr; 183(4):1587-602. PubMed ID: 8666917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies.
    Junghans RP; Carrasquillo JA; Waldmann TA
    Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1752-7. PubMed ID: 9465089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in interleukin 2 receptor targeted treatment.
    Morris JC; Waldmann TA
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i109-14. PubMed ID: 11053100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
    Junghans RP; Dobbs D; Brechbiel MW; Mirzadeh S; Raubitschek AA; Gansow OA; Waldmann TA
    Cancer Res; 1993 Dec; 53(23):5683-9. PubMed ID: 8242624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.
    Junghans RP; Waldmann TA; Landolfi NF; Avdalovic NM; Schneider WP; Queen C
    Cancer Res; 1990 Mar; 50(5):1495-502. PubMed ID: 2406013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors.
    Webber KO; Kreitman RJ; Pastan I
    Cancer Res; 1995 Jan; 55(2):318-23. PubMed ID: 7812965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment.
    Kobayashi H; Yoo TM; Kim IS; Kim MK; Le N; Webber KO; Pastan I; Paik CH; Eckelman WC; Carrasquillo JA
    Cancer Res; 1996 Aug; 56(16):3788-95. PubMed ID: 8706025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
    Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
    Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody.
    Kingsbury GA; Waldmann TA; Junghans RP
    Leukemia; 1998 Jun; 12(6):982-91. PubMed ID: 9639430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points.
    Kobayashi H; Le N; Kim IS; Kim MK; Pie JE; Drumm D; Paik DS; Waldmann TA; Paik CH; Carrasquillo JA
    Cancer Res; 1999 Jan; 59(2):422-30. PubMed ID: 9927057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity.
    Jacques Y; Le Mauff B; Boeffard F; Godard A; Soulillou JP
    J Immunol; 1987 Oct; 139(7):2308-16. PubMed ID: 2821110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysical characterization of a recombinant soluble interleukin 2 receptor (Tac). Evidence for a monomeric structure.
    Junghans RP; Stone AL; Lewis MS
    J Biol Chem; 1996 May; 271(18):10453-60. PubMed ID: 8631840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine receptor-directed therapy: a model of immune intervention.
    Waldmann TA; Grant A; Tendler C; Greenberg S; Goldman C; Bamford R; Junghans RP; Nelson D
    J Clin Immunol; 1990 Nov; 10(6 Suppl):19S-28S; discussion 28S-29S. PubMed ID: 2081786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.
    Junghans RP; Anderson CL
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5512-6. PubMed ID: 8643606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.
    Brown PS; Parenteau GL; Dirbas FM; Garsia RJ; Goldman CK; Bukowski MA; Junghans RP; Queen C; Hakimi J; Benjamin WR
    Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2663-7. PubMed ID: 2011577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement and biological correlates of antibody bioactivity during antibody immunotherapies.
    Hagg DS; Junghans RP
    J Immunol Methods; 1998 Oct; 219(1-2):7-21. PubMed ID: 9831385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts.
    Choi CW; Lang L; Lee JT; Webber KO; Yoo TM; Chang HK; Le N; Jagoda E; Paik CH; Pastan I
    Cancer Res; 1995 Nov; 55(22):5323-9. PubMed ID: 7585595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment.
    Wu C; Jagoda E; Brechbiel M; Webber KO; Pastan I; Gansow O; Eckelman WC
    Bioconjug Chem; 1997; 8(3):365-9. PubMed ID: 9177842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.